Calcium

Clinical Summary

Calcium is the body's most abundant mineral — 99% stored in bones and teeth as hydroxyapatite, 1% in blood and soft tissues tightly regulated at 8.5–10.5 mg/dL. It serves structural (bone mineralization), signaling (intracellular second messenger), neuromuscular (muscle contraction, nerve transmission), and hemostatic (coagulation cascade cofactor) roles.

Where the evidence is strong: Combined with Vitamin D3, calcium reduces fracture risk 15–26% in elderly and deficient populations (PMID 31860103, 15886381). Rickets/osteomalacia are preventable and reversible with adequate calcium + D3.

Where evidence has been downgraded: The 2025 Cochrane update on calcium for preeclampsia (PMID 41330480) excluded 20 previously included trials (9 for trustworthiness) and now shows calcium "may result in little to no difference" in preeclampsia (RR 0.83, CI 0.67–1.04, NOT significant). The sensitivity analysis of large trials only (>95% of participants) confirms "little to no difference" with HIGH-certainty evidence. This is a major downgrade from the 2018 Cochrane which showed 52% reduction. WHO still recommends calcium for low-Ca populations, and other meta-analyses still show benefit, but the most rigorous analysis weakens this claim substantially.

Where the evidence has shifted (2024–2026): The cardiovascular safety debate has intensified. A 2025 UK Biobank study (n=480,972) linked calcium supplements to increased arrhythmia risk (AF HR 1.20, PMID 40315789). Reid 2025 argued calcium supplements are obsolete for fracture prevention, noting 10–20% increased MI risk and acute 8-hour post-dose spikes in coagulability and calcification propensity (PMID 39937345). Calcium supplementation in diabetics specifically showed increased CVD mortality (HR 1.67, PMID 37506393). A Mendelian randomization study flagged T2D risk (OR 3.40, PMID 40406923). Meanwhile, CRC protection was confirmed at large scale — 29% risk reduction in the NIH-AARP cohort (PMID 39960668).

Bottom line: Calcium remains essential for bone health, but the risk-benefit calculus for supplementation has become more nuanced. Dietary calcium is consistently safer than supplemental calcium. When supplementing, use lowest effective dose with D3 + K2 + Mg, split doses, and avoid >500 mg boluses.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=OA caps at 3/5.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Critical dosing principle: Absorption efficiency drops sharply above 500 mg/dose (active transport saturates). Always split doses.

Condition-Specific Protocols

Osteoporosis / Osteopenia Protocol

Evidence: 5/5 | Key PMIDs: 31860103, 15886381, 16481635

Phase 1: Assessment (Weeks 1–2)

• DEXA scan baseline, serum Ca, 25(OH)D, PTH, creatinine/eGFR
• Assess dietary Ca intake (food diary or validated questionnaire)
• Calculate supplement gap: target 1200 mg/d total minus dietary intake

Phase 2: Therapeutic (Weeks 3–52)

• Ca: 1000–1200 mg/d total (supplement the gap, not the full amount)
• Vitamin D3: 800–2000 IU/d (target serum 25(OH)D >30 ng/mL, ideally 40–50)
• Vitamin-K2 (MK-7): 180 mcg/d (directs Ca to bone, inhibits vascular calcification)
• Magnesium: 200–400 mg/d (maintain Ca:Mg ~2:1)
• Formulation: Calcium-Citrate preferred (elderly, PPI users); carbonate acceptable with meals

Phase 3: Maintenance (Year 1+)

• DEXA every 1–2 years; serum Ca + D annually
• Expected: 0.5–2% BMD/yr increase; 15–20% fracture risk reduction over 2–3 years
• Ca alone is insufficient — combine with weight-bearing exercise and, if indicated, bisphosphonates or other Rx

Drug Interaction Timing: Bisphosphonates: take fasted upon waking, Ca ≥2h later. Levothyroxine: 4h apart. Stop/Reassess: If serum Ca >10.5 mg/dL, if kidney stones develop, if on thiazides + high-dose Ca (hypercalcemia risk)

Preeclampsia Prevention Protocol (EVIDENCE DOWNGRADED 2025)

Evidence: 4/5 (downgraded from 5/5) | Key PMIDs: 41330480, 30277579, 38197817

CRITICAL UPDATE (2025 Cochrane, PMID 41330480): After excluding 20 previously included trials (9 for trustworthiness), the updated Cochrane review found calcium "may result in little to no difference" in preeclampsia (RR 0.83, CI 0.67–1.04 — NOT statistically significant, low-certainty evidence). Sensitivity analysis of large trials only showed "little to no difference" with HIGH-certainty evidence (RR 0.92, CI 0.79–1.05). The dramatic 52% reduction from the 2018 Cochrane (PMID 30277579) relied partly on studies now flagged for trustworthiness issues. WHO still recommends calcium in low-Ca populations, and a 2026 NMA (PMID 41819984) still shows gestational HTN benefit (OR 0.55), but the preeclampsia-specific evidence has weakened substantially.

Phase 1: Initiation (Preconception or <20 weeks gestation)

• Assess dietary Ca intake. If <600 mg/d → start supplementation per WHO guidance.
• Dose: 1500–2000 mg/d elemental Ca (WHO recommendation; evidence base now weaker)
• Split: 500 mg 3×/day with meals
• Formulation: Calcium-Carbonate (most studied) or Calcium-Citrate if GI upset
• Space ≥2h from prenatal iron

Phase 2: Therapeutic (20 weeks → delivery)

• Continue 1500–2000 mg/d through pregnancy
• Monitor serum Ca if symptomatic

Dose note: NEJM 2024 (PMID 38197817) tested 500 mg vs 1500 mg (not vs placebo) and found 500 mg noninferior for preeclampsia. But preeclampsia rates were low in both groups (~3%), and neither was compared to no supplementation.

Expected Outcomes: Gestational HTN reduction (OR 0.55 in NMA); preeclampsia benefit uncertain per 2025 Cochrane; preterm birth <37 wk may be reduced (RR 0.80, PMID 39560075 — but very low certainty); aspirin+calcium combination may be superior (OR 0.12, PMID 41819984).

Safety

Interactions Table

Contraindications

• Absolute: Hypercalcemia (>10.5 mg/dL), uncontrolled hyperparathyroidism, active sarcoidosis, severe renal impairment (GFR <30 without dialysis), hypercalciuria with recurrent kidney stones (>300 mg/24h urinary Ca)
• Relative: History of calcium oxalate stones (use citrate form + hydration), moderate renal impairment (GFR 30–60, reduce dose), digoxin use, thiazide diuretic use with >1000 mg/d supplement, diabetes (emerging CVD signal — see below)

Adverse Effects

FAERS Signal Table (from BioMCP)

Reading FAERS data: Calcium FAERS data is predominantly noise from polypharmacy contexts. "Calcium" matches calcium-containing drugs (atorvastatin calcium, rosuvastatin calcium, calcium acetate for CKD). The CKD signal (6,204 reports) reflects CaCO3 use as a phosphate binder in renal failure patients, not oral supplementation causing kidney disease. Diarrhoea and nausea are the only plausible supplement-attributable reactions. No cardiovascular signal appeared in FAERS top-10 for any calcium form.

Monitoring Table

Special Populations

Renal Impairment

Cardiovascular Disease (EMERGING CONCERN — 2024–2026 Data)

Current evidence status: Conflicting but increasingly concerning for supplement-form calcium.

• Reid 2025 (PMID 39937345): calcium bolus raises circulating Ca for ~8h with acute increases in blood coagulability, calcification propensity, and BP >5 mmHg above placebo. Mendelian randomization confirms circulating calcium is a CVD risk factor.
• Chen 2025 UK Biobank (PMID 40315789, n=480,972): calcium supplements associated with ↑ total arrhythmias (HR 1.11), AF/AFL (HR 1.20), ventricular arrhythmia (HR 1.14), bradyarrhythmia (HR 1.18).
• Qiu 2024 UK Biobank (PMID 37506393, n=434,374): calcium supplements associated with ↑ CVD incidence (HR 1.34), CVD mortality (HR 1.67), all-cause mortality (HR 1.44) — IN DIABETICS ONLY. No significant association in non-diabetics.
• Bolland 2010 (PMID 20671013): original signal — Ca supplements ↑ MI risk (HR 1.27).
• Huo 2023 (PMID 37181938): no significant CVD risk increase.
• Ayer 2026 (PMID 40780566): review confirms some evidence of ↑ CHD risk with Ca alone; vitamin D effect neutral.

Clinical implications:

• Prioritize dietary calcium sources when possible (no CV signal for food-source Ca)
• If supplementing: use lowest effective dose, combine with Vitamin-K2 (180 mcg/d) to inhibit vascular calcification
• Split doses (avoid >500 mg bolus — the acute coagulability spike is bolus-related)
• In diabetics: use extreme caution; discuss with physician before starting calcium supplements
• Combine with Vitamin D3 (neutral CV effect; essential for Ca metabolism)

Type 2 Diabetes Risk (EMERGING — 2025 Data)

A 2025 Mendelian randomization + FAERS study (PMID 40406923) found genetic signatures predicting calcium supplementation were associated with increased T2D risk (OR 3.40). FAERS data showed ROR 4.27 for T2D among calcium adverse events. This is a single study requiring replication, but the MR design reduces confounding concerns. Combined with the Qiu 2024 finding that calcium supplements are dangerous specifically for diabetics, this creates a concerning bidirectional signal: calcium supplements may promote T2D, and T2D patients on calcium supplements have worse CVD outcomes.

Synergies & Stacking

The "bone stack" (community + clinical consensus): Ca + D3 + K2 (MK-7) + Mg. This is the standard of care and the dominant community protocol (see Community section).

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No compound-relevant variants for MTHFR, COMT, APOE, BCMO1, CYP, SOD2, or SLC23A for calcium specifically.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-Negative across ~500+ Reddit reports, ~50–100 Longecity participants, and biohacker YouTube channels. Calcium is one of the few supplements where the dominant community narrative is against supplementation.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Moderate — Amway Nutrilite calcium is a top seller in Korea/SEA. No other major MLM specifically targeting calcium detected.
• Influencer concentration: Opposite of typical — major influencers (Huberman, Brecka, Dr. Berg) are skeptical of calcium supplementation. No pro-calcium influencer hype.
• Astroturfing signals: Low. Dairy industry funds "calcium from food" messaging (aligned with scientific consensus). Some anti-supplement messaging may be amplified by bisphosphonate manufacturers (cui bono).
• Commercial bias: Calcium supplements are commodity-priced; no significant premium-product hype.

Folk vs Clinical Reality Check

Community skepticism about calcium supplements is more aligned with recent evidence than the clinical establishment's blanket "everyone should supplement" messaging. The community's emphasis on food-first calcium, the bone stack (D3+K2+Mg), and CV risk awareness reflects a sophisticated synthesis of the literature. Where the community gets it wrong: under-dosing relative to actual deficiency, and extending CV risk data (which applies to high-dose boluses) to all calcium supplementation contexts. East Asian communities (Japan, Korea) are more supplement-positive due to documented population-level deficiency — this is epidemiologically justified.

Deep Dive: Mechanisms & Research

Calcium Homeostasis

Serum calcium is tightly regulated at 8.5–10.5 mg/dL by three hormones:

• PTH: Released when serum Ca drops → ↑ bone resorption, ↑ renal reabsorption, ↑ D3 activation → ↑ intestinal absorption
• Calcitonin: Released when serum Ca rises → ↓ bone resorption, ↑ renal excretion
• Calcitriol (1,25(OH)₂D): Active Vitamin D3 → ↑ intestinal Ca absorption via calbindin-D upregulation

Absorption Physiology

Two mechanisms in duodenum/proximal jejunum:

1. Active transport (saturable): Transcellular via calbindin-D. Efficient <500 mg/dose. Upregulated by D3, downregulated when replete. Declines with age.
2. Passive diffusion (non-saturable): Paracellular. Dominates at >500 mg/dose. Not hormonally regulated. Lower per-unit efficiency.

This is why split dosing matters: active transport saturates above ~500 mg elemental Ca per dose.

Cardiovascular Mechanism (How Supplements May Cause Harm)

Reid 2025 (PMID 39937345) proposed the mechanism: a calcium supplement bolus causes an acute 8-hour spike in serum ionized Ca, which:

1. Increases blood coagulability (Ca²⁺ is Factor IV in coagulation cascade)
2. Increases calcification propensity score (promotes hydroxyapatite deposition in soft tissues)
3. Raises BP >5 mmHg above placebo acutely
4. This does NOT occur with dietary calcium (absorbed gradually over hours of digestion)

This explains why dietary calcium is consistently safe while supplemental boluses carry risk — the pharmacokinetics differ.

Emerging: Calcium in GI Health

• CaSR (calcium-sensing receptor) signaling is critical in GI tract: regulates smooth muscle contractility, acid secretion, epithelial barrier integrity, and immune signaling (PMID 41201222)
• Calcium butyrate (500 mg/d for 8 weeks) reduced pediatric IBS symptoms (73% vs 3.8% placebo; PMID 40635319) — increased SCFA-producing bacteria and decreased pro-inflammatory taxa. Note: this is calcium butyrate, a distinct compound from standard calcium supplements.
• Calcium-powered probiotics can reconfigure intestinal biofilms (preclinical, PMID 41467626)

Emerging: T2D Risk Signal

Mendelian randomization (PMID 40406923): genetic signatures predicting calcium supplementation associated with T2D risk (OR 3.40). FAERS mining within the same study: ROR 4.27 for T2D adverse events. Combined with Qiu 2024's finding that calcium supplements worsen CVD outcomes specifically in diabetics (PMID 37506393), this suggests a calcium-metabolic disease axis that needs urgent investigation. Mechanism hypothesis: sustained hypercalcemia may impair beta-cell function or promote insulin resistance.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status (from BioMCP)

• FDA: GRAS dietary supplement (no NDA). Calcium acetate approved as phosphate binder for CKD (ANDA202315). No formal FDA safety review of supplement-dose calcium exists.
• EMA: No standalone calcium supplement authorization. Included in combination products.
• Regulatory context: Calcium supplements operate under OTC monograph / DSHEA framework, not NDA approval. Commercial viability is high but patent protection is impossible (commodity mineral). This means no company funds large safety RCTs.

Ataraxia Verdict (as of 2026-04-15)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• No supplement hype: Calcium is the opposite — a "boring" supplement with no influencer enthusiasm. The hype, if any, is historical: decades of "milk builds strong bones" dairy industry messaging.
• Hasty generalization detected: Extrapolating from elderly/deficient populations to "everyone should supplement." USPSTF explicitly says insufficient evidence for community-dwelling non-osteoporotic adults.
• Cherry-picking on both sides: Pro-supplement advocates cite bone RCTs while ignoring CV signals. Anti-supplement advocates cite Bolland 2010 while ignoring that dietary Ca and combined Ca+D3+K2 have different risk profiles.
• Appeal to nature: "Coral calcium" and "oyster shell calcium" marketed as "natural" despite higher heavy metal contamination risk.

Evidence Gaps

1. No large RCT comparing calcium forms (carbonate vs citrate vs MCHC) for long-term bone outcomes — only bioavailability comparisons exist
2. CV risk unresolved: No properly powered RCT with cardiovascular endpoints for Ca supplementation. Bolland vs Huo MAs reach opposite conclusions from the same data.
3. T2D signal needs replication: One MR study (PMID 40406923) is insufficient to establish causation despite strong design
4. Optimal Ca:Mg ratio: Traditional 2:1 is theoretical; no RCT data testing different ratios
5. Calcium + gut microbiome: Mechanistic plausibility (CaSR signaling) but no human supplementation trials
6. VDR pharmacogenomics: Known variants affect response, but no clinical decision algorithm exists
7. Men are understudied: Most bone health RCTs are 80–90% female
8. Low-dose preeclampsia paradox: NEJM 2024 showed 500 mg/d fails; threshold between 500 and 1000 mg/d unknown

Bias Flags (Mode 4: First Principles)

• Assumption 1: "Serum calcium reflects bone health" — FALSE. Normal serum Ca can coexist with severe osteoporosis. Serum Ca is tightly homeostatic; it reflects PTH function, not bone stores.
• Assumption 2: "More calcium = stronger bones" — FALSE ABOVE THRESHOLD. Dose-response curve plateaus at ~1200 mg/d total; excess may cause harm (stones, CV risk).
• Assumption 3: "Calcium supplements = dietary calcium" — FALSE. Pharmacokinetics differ fundamentally. Supplements cause acute serum spikes; dietary Ca is absorbed gradually. This explains the CV risk differential.
• First principles: The body needs ~1000–1200 mg/d calcium (true). Absorption is saturable (true). The form and rate of delivery matter (true). Safety concerns are bolus-related, not compound-related (likely true but needs confirmation).

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Calcium supplement market is commodity-driven ($2.4B globally). No proprietary blends or "clinical strength" scams — calcium is calcium. Marketing tends toward fear-based ("you're not getting enough") rather than aspiration-based.
• Influencer economics: No significant pro-calcium influencer ecosystem. The biohacker/wellness influencer world is actually anti-calcium-supplement.
• Counter-narrative manipulation: Bisphosphonate manufacturers (Merck, Amgen) benefit from calcium being seen as "insufficient" for osteoporosis — creating demand for prescription alternatives. Cui bono: both the supplement industry AND pharma have aligned incentives for different reasons.
• Cui bono summary: Supplement companies sell cheap Ca products at modest margins. Dairy industry promotes dietary Ca (aligned with evidence). Pharma sells expensive bone drugs when Ca "isn't enough." No single actor dominates the narrative.
• Red team highlight: The most concerning angle is the absence of a definitive CV safety trial. No company will fund it (supplements are unpatentable; pharma has no incentive). This information gap persists because the economic incentives are misaligned.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — essential foundational mineral with strong evidence for bone health, pregnancy, and documented deficiency states; general utility is condition-gated (dietary intake, life stage, deficiency) rather than broadly prophylactic.
• Opportunity cost: Adding calcium supplements adds pill burden, interaction management (timing around thyroid meds, iron, etc.), and uncertain CV risk. For someone eating dairy/greens regularly, supplementation may provide no net benefit.
• Verdict: CONDITIONAL
• Conditions: Supplement only if: (1) dietary Ca intake <800 mg/d, (2) documented osteopenia/osteoporosis, (3) pregnancy in low-Ca population, (4) on corticosteroids, (5) malabsorption conditions (celiac, IBD, gastric bypass). If none apply, dietary calcium is sufficient and safer.

Bottom Line

Calcium is an essential mineral with 5/5 evidence for bone health (with D3) and preeclampsia prevention. However, the 2024–2026 evidence has made calcium supplementation more nuanced: CV risk signals are now quantified (arrhythmia, MI, mortality in diabetics), a T2D signal has emerged, and the preeclampsia benefit appears dose-dependent (≥1g/d required). The community's food-first consensus is well-calibrated to the evidence. Supplement when there's a documented gap, use citrate form at ≤500 mg/dose, always pair with D3+K2+Mg, and avoid in diabetics without compelling indication. The bone stack (Ca+D3+K2+Mg) remains the standard of care for those who need supplementation.

Practical Notes

Brands & Product Selection

Quality markers: USP Verified > NSF Certified > ConsumerLab Approved. Look for: lot number, expiration date, elemental calcium content stated, third-party testing seal.

Red flags: No testing seal, proprietary blends, "coral calcium" or "oyster shell" without heavy metal testing (lead risk), unrealistic health claims, no lot number.

Budget: Kirkland Signature (USP), Nature Made (USP), CVS/Walgreens store brands (USP). Mid-range: Thorne Research (NSF), Pure Encapsulations, NOW Foods. Premium: Jarrow Formulas (Bone-Up MCHC), Life Extension.

Storage & Handling

Room temperature (15–25°C), dry, tightly closed. 2–3 yr shelf life unopened; 18–24 mo after opening. Minimal degradation risk — calcium salts are stable.

Palatability & Compliance

Carbonate is chalky; citrate slightly tart. Chewable CaCO3 (e.g., Tums) is palatable but per-tablet dose is low. Powder can mix into smoothies/juice for dose precision. Compliance is the #1 predictor of efficacy — choose the form you'll actually take consistently.

Exercise & Circadian Timing

• No acute exercise interaction. Weight-bearing exercise synergizes with Ca for BMD (PMID 41470812).
• Evening dosing theoretically offsets nocturnal bone resorption, but no clinical evidence of superiority over AM dosing.
• Timing matters more for interactions (levothyroxine, iron, bisphosphonates) than for calcium efficacy itself.

Reference Ranges (Expected Biomarker Changes)

Cost

What We Don't Know

• Whether the CV risk signal is a class effect of all calcium supplements or specific to bolus dosing of carbonate. No RCT will answer this — economic incentives are misaligned.
• The threshold dose for preeclampsia prevention (500 mg fails, ≥1000 mg works — what about 750?).
• Whether VDR/CaSR genotyping could personalize calcium dosing. Evidence exists but no clinical algorithm.
• Long-term effects of the Ca+D3+K2 combination on vascular calcification vs bone density — K2 is the theoretical solution, but multi-year RCT data is limited.
• Whether the T2D signal (MR OR 3.40) replicates across populations and designs.
• Optimal Ca:Mg ratio — 2:1 is convention, not evidence-based.
• Whether calcium butyrate's IBS benefit extends to adults and other GI conditions.
• Sex-specific calcium pharmacokinetics — men are understudied for a compound where most evidence comes from postmenopausal women.
• How the gut microbiome modulates calcium absorption and whether probiotics could enhance it.

References

Systematic Reviews & Meta-Analyses

1. Yao P et al. (2019) Vitamin D and Calcium for the Prevention of Fracture. JAMA Netw Open 2(12):e1917789. PMID: 31860103 — Ca+D3 reduced fracture risk 15% in MA of 33 RCTs (N=51,145)
2. Bischoff-Ferrari HA et al. (2005) Fracture prevention with vitamin D supplementation. JAMA 293(18):2257-64. PMID: 15886381 — D3+Ca reduced hip fractures 26% (N=9,820)
3. Cluver CA et al. (2025) Calcium supplementation during pregnancy for preventing hypertensive disorders. Cochrane Database Syst Rev. PMID: 41330480 — Updated Cochrane confirming preeclampsia benefit
4. Cluver CA et al. (2025) Calcium supplementation commenced before pregnancy for preventing hypertensive disorders. Cochrane Database Syst Rev. PMID: 40965861 — Pre-pregnancy calcium Cochrane review
5. Hofmeyr GJ et al. (2018) Calcium supplementation during pregnancy for preventing hypertensive disorders. Cochrane Database Syst Rev. PMID: 30277579 — Ca ≥1g/d reduced preeclampsia 52% in low-Ca populations (N=18,587)
6. Wu Y et al. (2026) Preventive effects of different interventions on gestational hypertension. J Matern Fetal Neonatal Med. PMID: 41819984 — NMA (50 RCTs, N=57,836): Ca reduces gestational HTN (OR 0.55); aspirin+Ca most effective
7. Bai J et al. (2025) Exercise + Ca/VitD on BMD in Postmenopausal Women. Nutrients. PMID: 41470812 — MA: exercise + Ca/VitD improves lumbar spine (SMD 0.31) and femoral neck BMD (SMD 0.47)
8. Wei Y et al. (2025) Dietary supplements on bone turnover markers in postmenopausal women. PeerJ. PMID: 40949733 — NMA (43 RCTs): Ca best for ALP; VitD+K best for P1NP/osteocalcin
9. Amer MA et al. (2025) Calcium supplementation and blood pressure. BMC Complement Med Ther. PMID: 40045266 — MA (40 studies): Ca reduces DBP −2.04 mmHg but NOT SBP
10. Zouiouich S et al. (2025) Calcium intake and CRC risk. JAMA Netw Open. PMID: 39960668 — NIH-AARP (N=471,396): 29% lower CRC risk at highest Ca intake
11. Xiong K et al. (2025) Calcium intake and prostate cancer risk. J Trace Elem Med Biol. PMID: 40222344 — Dose-response MA: ↑ prostate cancer risk at high Ca intake
12. Bolland MJ et al. (2010) Calcium supplements and risk of MI. BMJ. PMID: 20671013 — MA: Ca supplements ↑ MI risk (HR 1.27)
13. Huo X et al. (2023) Calcium Supplements and Risk of CVD. Curr Dev Nutr. PMID: 37181938 — MA: no significant CVD risk increase (contradicts Bolland)
14. Li Z et al. (2023) Calcium Supplementation and CVD/Stroke Risk. Heart Lung Circ. PMID: 37743221 — SR + MA on CVD risk
15. Veronese N et al. (2025) Preventing and treating kidney stones: umbrella review. Minerva Urol Nephrol. PMID: 40891477
16. Jaiswal V et al. (2024) Ca and gestational HTN/preeclampsia. Curr Probl Cardiol. PMID: 38013011 — MA of 26 RCTs
17. Zhu Q et al. (2024) Ca for gestational hypertension prevention. Pregnancy Hypertens. PMID: 39608269
18. Kumsa H et al. (2025) Ca for preeclampsia: umbrella review. Front Med. PMID: 40109721
19. Robinson J et al. (2025) Nutritional interventions for PMS. Nutr Rev. PMID: 38684926 — SR of RCTs
20. Fu T et al. (2026) Risk factors for osteoporosis in RA. Osteoporos Int. PMID: 41188646

Landmark RCTs

21. Hofmeyr GJ et al. (2019) Prepregnancy calcium for pre-eclampsia prevention (CAPPO Trial). Lancet. PMID: 30696573 — 500 mg 2×/d reduced preeclampsia recurrence
22. Dwarkanath P et al. (2024) Two RCTs of Low-Dose Calcium in Pregnancy. N Engl J Med. PMID: 38197817 — LOW-DOSE (500 mg/d) FAILED to reduce preeclampsia — dose-dependent effect
23. Jackson RD et al. (2006) Ca + D3 and fracture risk (WHI Trial). N Engl J Med. PMID: 16481635 — N=36,282 postmenopausal women; hip fracture ↓ in compliant participants
24. Rondanelli M et al. (2024) Ca citrate 500 mg/d in elderly osteopenic. Aging Clin Exp Res. PMID: 38345765 — 3.9% AE rate; BP decreased (−2.8/−2.1 mmHg)
25. Cristofori F et al. (2025) Ca butyrate for pediatric IBS. J Pediatr Gastroenterol Nutr. PMID: 40635319 — 73% vs 3.8% symptom reduction
26. Saha D et al. (2026) Cholecalciferol + Ca for hypovitaminosis D. Clin Endocrinol. PMID: 41614349 — Improved BMD but NOT trabecular bone score

Epidemiological & Observational

27. Chen Y et al. (2025) Ca supplements and arrhythmia risk. UK Biobank (n=480,972). J Nutr Health Aging. PMID: 40315789 — AF HR 1.20, VA HR 1.14, bradyarrhythmia HR 1.18
28. Qiu L et al. (2024) Ca supplements, CVD, and mortality in diabetics. UK Biobank (n=434,374). Diabetes Care. PMID: 37506393 — CVD HR 1.34, CVD mortality HR 1.67 IN DIABETICS ONLY
29. Zhao J et al. (2025) MR + FAERS: Ca supplementation and T2D risk. Food Funct. PMID: 40406923 — MR OR 3.40; FAERS ROR 4.27

Reviews & Mechanisms

30. Reid IR (2025) Calcium supplements: benefits, risks, and current recommendations. Curr Osteoporos Rep. PMID: 39937345 — LANDMARK: Ca supplements don't prevent fractures in community-dwelling adults; 10–20% MI risk increase; acute coagulability spike mechanism
31. Ayer A et al. (2026) Ca supplementation and CHD risk. Trends Cardiovasc Med. PMID: 40780566
32. Zheng Y et al. (2025) Calcium in GI disorders. Int J Vitam Nutr Res. PMID: 41201222 — CaSR signaling in motility, barrier, immunity, microbiome
33. Chung M et al. (2016) Calcium Intake and CVD Risk. Ann Intern Med. PMID: 27776363 — USPSTF evidence review: small BP reduction
34. Michos ED et al. (2021) Vitamin D, Calcium, and CV Health. JACC Focus Seminar. PMID: 33509400
35. He Z et al. (2025) Calcium and calcinosis cutis in autoimmune. J Cutan Med Surg. PMID: 40072480 — Ca supplements may promote skin calcification in scleroderma/dermatomyositis
36. Kahwati LC et al. (2018) USPSTF Fracture Prevention Evidence. JAMA. PMID: 29677308

Disease-Specific

37. Benchimol EI et al. (2007) Ca + D3 on BMD in pediatric IBD. J Pediatr Gastroenterol Nutr. PMID: 18030230
38. Bernstein CN et al. (2004) Osteoporosis and IBD. Aliment Pharmacol Ther. PMID: 15113361
39. Caruso R et al. (2013) Nutrient supplementation in celiac disease. Ann Med. PMID: 24195595
40. Zanchetta MB et al. (2016) Bone and Celiac Disease. Curr Osteoporos Rep. PMID: 26875096
41. Bargagli M et al. (2021) Calcium/D3 and kidney stone disease. Nutrients. PMID: 34959915

Pregnancy-Specific

42. Kongwattanakul K et al. (2024) Ca supplementation for other pregnancy/infant outcomes. Cochrane Database Syst Rev. PMID: 39560075 — Reduces preterm birth <37 wk (RR 0.80)
43. Gerede A et al. (2025) Ca supplementation in pregnancy. Medicina. PMID: 40731825
44. Wright D et al. (2024) Challenging the evidence from MAs on Ca for preeclampsia. BJOG. PMID: 38302677
45. de Brito Pitilin E et al. (2024) Ca and cytokines/oxidative stress in pregnancy. BMC Pregnancy Childbirth. PMID: 38245691

Guidelines

46. RACGP + Healthy Bones Australia (2024/2025) Guideline for osteoporosis. Med J Aust. PMID: 40134107
47. ESC/EAPC (2025) Diet and nutrition in CVD prevention. Eur J Prev Cardiol. PMID: 40504596

Pharmacogenomics

48. Yaghoobi A et al. (2024) VDR rs4516035 and osteoporosis. J Res Health Sci. PMID: 39072539
49. Young R et al. (2003) CaSR A986S polymorphism and calcium response. JCEM. PMID: 12574201

Other

50. Grgic J et al. (2026) Dietary supplement use in 2,877 centenarians. Geroscience. PMID: 40624287
51. Souroujon Torun AA et al. (2026) Nutrition in prostate cancer risk. Clin Nutr ESPEN. PMID: 41520878